RTRuben Tavares

Ruben Tavares

*This is an algorithmically generated author record based on publicly available information.

Ruben Tavares has a total of 32 co-authors. Here are the top co-authors by number of shared publications:

  • Mary J. Bell

    UNCOVER Clinical Research Company, Milton, Department of Medicine, Division of Rheumatology, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada, Hospital for Special Surgery, New York, NY, USA and Mt Sinai Hospital, Toronto, Ontario, Canada

    4 shared publications
  • Vivian P. Bykerk

    UNCOVER Clinical Research Company, Milton, Department of Medicine, Division of Rheumatology, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada, Hospital for Special Surgery, New York, NY, USA and Mt Sinai Hospital, Toronto, Ontario, Canada

    4 shared publications
  • Andreas Laupacis

    2 shared publications
  • Arthur A.M. Bookman

    2 shared publications
  • Avril A. Fitzgerald

    2 shared publications
  • Boulos Haraoui

    2 shared publications

Latest Publications

  • Open Access

    A parallel group cohort to determine the measurement properties of an early inflammatory arthritis detection tool

    by Ruben Tavares, Selena Huang, Vivian P. Bykerk, Mary J. Bell

    Objectives. To determine the comprehensibility, internal consistency, test–retest reliability and discriminative properties of an early inflammatory arthritis (IA) detection tool. Methods. Four groups were recruited from outpatient clinics at two tertiary care hospitals: early IA, established IA, non-IA musculoskeletal conditions (MSK) and non-MSK. Participants attended a study visit where they completed the 11-item tool with binary yes/no response options. Comprehensibility was assessed for each tool item on a 5-point Likert scale. For test–retest assessment, the tool was mailed to participants following a 2-week recall washout interval. Two items were randomly selected to test internal consistency. Discriminative properties compared tool item responses with blinded rheumatologist clinical assessments. A previously developed rheumatology triage algorithm was externally validated. Results. A total of 170 participants were enrolled in the study. Comprehensibility approached unity for all tool items. The internal consistency Kuder-Richardson Formula 20 was 0.985 (P < 0.0001). The mean test–retest reliability kappa (s.d.) was 0.81 (0.02). The intraclass correlation coefficient (ICC) (95% CI) for summed yes responses between test and retest phases was 0.94 (0.93, 0.95) and for algorithm scores was 0.97 (0.96, 0.98). Patient responses were significantly associated with the corresponding clinical evaluations (P < 0.0001, respectively). The sum of yes responses and rheumatology triage algorithm scores both differentiated early IA from each of the other three groups (P < 0.004, respectively). The scoring algorithm receiver operating characteristic plot area under the curve (s.e.) was 0.829 (0.003). Conclusion. The tool has favourable measurement and discriminative properties. The discriminative properties of the rheumatology triage scoring algorithm were externally validated.


  • Time to Disease-modifying Antirheumatic Drug Treatment in Rheumatoid Arthritis and Its Predictors: A National, Multicenter, Retrospective Cohort

    by Ruben Tavares, Janet E. Pope, Jean-Luc Tremblay, Carter Thorne, Vivian P. Bykerk, Juris Lazovskis, Kenneth L.N. Blocka, Mary J. Bell, Diane Lacaille, Carol A. Hitchon, et al.

    Objective. To determine the proportion of patients with rheumatoid arthritis (RA) under rheumatologic care treated with disease-modifying antirheumatic drugs (DMARD) within 6 months from symptom onset and the components of time to treatment and its predictors. Methods. A historical inception cohort of 339 patients with RA randomly selected from 18 rheumatology practices was audited. The proportion that initiated DMARD treatment within 6 months from symptom onset was estimated using Kaplan-Meier analysis. Time to each component of the care pathway was estimated. Multivariable modeling was used to determine predictors of early treatment using 12 preselected variables available in the clinical charts. Bootstrapping was used to validate the model. Results. Within 6 months from symptom onset, 41% (95% CI 36%−46%) of patients were treated with DMARD. The median time to treatment was 8.4 (interquartile range 3.8−24) months. Events preceding rheumatology referral accounted for 78.1% of the time to treatment. The most prominent predictor of increased time to treatment was a concomitant musculoskeletal condition, such as osteoarthritis or fibromyalgia. The significance of other variables was less consistent across the models investigated. Included variables accounted for 0.69 ± 0.03 of the variability in the model. Conclusion. Fewer than 50% of patients with RA are treated with DMARD within 6 months from symptom onset. Time to referral to rheumatology represents the greatest component delay to treatment. Concomitant musculoskeletal condition was the most prominent predictor of delayed initiation of DMARD. Implications of these and other findings warrant further investigation.


  • Open Access

    Early Management of Newly Diagnosed Rheumatoid Arthritis by Canadian Rheumatologists: A National, Multicenter, Retrospective Cohort

    by Ruben Tavares, Janet E. Pope, Jean-Luc Tremblay, Carter Thorne, Vivian P. Bykerk, Juris Lazovskis, Kenneth L.N. Blocka, Mary J. Bell, Diane Lacaille, Carol A. Hitchon, et al.

    Objective.: To describe early rheumatologic management for newly diagnosed rheumatoid arthritis (RA) in Canada.Methods.: A retrospective cohort of 339 randomly selected patients with RA diagnosed from 2001–2003 from 18 rheumatology practices was audited between 2005–2007.Results.: The most frequent initial disease-modifying antirheumatic drugs (DMARD) included hydroxychloroquine (55.5%) and methotrexate (40.1%). Initial therapy with multiple DMARD (15.6%) or single DMARD and corticosteroid combinations (30.7%) was infrequent. Formal assessment measures were noted infrequently, including the Health Assessment Questionnaire (34.6%) and Disease Activity Score for 28 joints (8.9%).Conclusion.: Initial pharmacotherapy is consistent with guidelines from the period. The infrequent reporting of multiple DMARD combinations and formal assessment measures has implications for current clinical management and warrants contemporary reassessment.


  • Classification of rheumatologic opinion on early inflammatory arthritis: Harmonization of a heterogeneous standard

    by Ruben Tavares, George A. Wells, Joel Scarf, Ria Cagaanan, Vivian P. Bykerk, Mary J. Bell

    Objective: Interrater variability limits rheumatologic opinion as a reference standard for early inflammatory arthritis (IA) classification. The study objectives were to determine whether rheumatologic opinion is associated with potential early IA classification methods despite high interrater variability, and to compare the relative strengths of those associations.Methods: Eighteen rheumatologists independently classified 30 initial rheumatology presentation summaries as early IA or not and recommended a pharmacotherapy. Case fulfillment of the following classification methods was independently determined: early referral to rheumatology recommendation for rheumatoid arthritis (ERRR), common early IA cohort inclusion criteria (CEAC), and prevalent IA classification criteria (American College of Rheumatology [ACR]/European Spondylarthropathy Study Group [ESSG]). Associations between rheumatologic opinion, disease‐modifying antirheumatic drug (DMARD) recommendation, and each classification method were determined.Results: Participating rheumatologists published on early IA and represented 3 continents. The median case was age 43 (interquartile range [IQR] 30–53) years, had 40 (IQR 24–104) weeks of symptoms, 60 (IQR 18–120) minutes of morning stiffness, a swollen joint count of 6 (IQR 1–13), and an erythrocyte sedimentation rate of 25 (IQR 10–51) mm/hour. The mean ± SD multiple‐rater kappa for rheumatologic opinion on early IA was 0.16 ± 0.02. The common odds ratios for associations between rheumatologic opinion and ERRR, CEAC, and ACR/ESSG were 10.3 (95% confidence interval [95% CI] 4.6–23.2), 4.4 (95% CI 2.5–7.7), and 0.7 (95% CI 0.4–1.1), respectively. Odds ratios for associations between DMARD recommendation and ERRR, rheumatologic opinion, CEAC, and ACR/ESSG were 18.7 (95% CI 8.1–43.2), 10.6 (95% CI 6.0–18.8), 2.8 (95% CI 1.7–4.6), and 0.5 (95% CI 0.3–0.7), respectively.Conclusion: Classification methods can be used to harmonize rheumatologic opinion of early IA despite high interrater variability. The ERRR is very strongly associated with both rheumatologic opinions of early IA and DMARD treatment recommendations.


  • Open Access

    Development of a self-administered early inflammatory arthritis detection tool

    by Mary J Bell, Ruben Tavares, Francis Guillemin, Vivian P Bykerk, Peter Tugwell, George A Wells

    BACKGROUND: Barriers to care limit the potential benefits of pharmacological intervention for inflammatory arthritis. A self-administered questionnaire for early inflammatory arthritis (EIA) detection may complement contemporary triage interventions to further reduce delays to rheumatologic care. The objective of this study was to develop a self-administered EIA detection tool for implementation in pre-primary care settings. METHODS: A core set of dimensions and constructs for EIA detection were systematically derived from the literature and augmented by investigative team arbitration. Identified constructs were formulated into lay language questions suitable for self-administration. A three-round Delphi consensus panel of EIA experts and stakeholders evaluated the relevance of each question to EIA detection and suggested additional items. Questions accepted by less than 70% of respondents in rounds one or two were eliminated. In round three, questions accepted by at least 80% of the panel were selected for the tool. RESULTS: Of 584 citations identified, data were extracted from 47 eligible articles. Upon arbitration of the literature synthesis, 30 constructs encompassing 13 dimensions were formulated into lay language questions and posed to the Delphi panel. A total of 181 EIA experts and stakeholders participated on the Delphi panel: round one, 60; round two, 59; and, round three, 169; 48 participated in all three rounds. The panel evaluated the 30 questions derived from the literature synthesis, suggested five additional items, and eliminated a total of 24. The eleven-question instrument developed captured dimensions of articular pain, swelling, and stiffness, distribution of joint involvement, function, and diagnostic and family history. CONCLUSIONS: An eleven-question, EIA detection tool suitable for self-administration was developed to screen subjects with six to 52 weeks of musculoskeletal complaints. Psychometric and performance property testing of the tool is ongoing.